Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

10x Genomics Q2 2024 GAAP EPS $(0.32) Beats $(0.48) Estimate, Sales $153.104M Beat $150.089M Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:28pm
10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 39.62 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $153.104 million which beat the analyst consensus estimate of $150.089 million by 2.01 percent. This is a 4.28 percent increase over sales of $146.819 million the same period last year.

Posted In: TXG


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist